Enter your terms above and click the 'Search' button.

Showing articles 0 to 9 of 9 Filter Applied: Parkinson disease,treatment of (Click to remove) Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease NEJM 356:39-46, Zanettini,R.,et al, 2007 Dopamine Agonists and the Risk of Cardiac Valve Regurgitation NEJM 356:29-38, Schade,R.,et al, 2007 Dopamine Agonists: Their Role in the Treatment of Parkinson's Disease JNNP 68;685-690, Brooks,D.J., 2000 Cabergoline Treatment of Early Parkinson's Disease:First Yr of Trtm Comparison of Cabergoline & Levodopa Neurol 48:363-368, Rinne,U.K.,et al, 1997 Multicenter, Placebo-Controlled Trial of Cabergoline Taken Once Daily in the Treatment of Parkinson's Disease Neurol 46:1062-1065, Hutton,J.T.,et al, 1996 Double-Blind Comparison of Cabergoline & Bromocriptine in Parkinson's Disease Pts with Motor Fluctuations Neurol 47:785-788, Inzelberg,R.,et al, 1996 Fluctuating Parkinson's Disease:Treatment with the Long-Acting Dopamine Agonist Cabergoline Arch Neurol 51:1236-1241, Ahlskog,J.E.,et al, 1994 Cabergoline in Parkinson's Disease:Long-Term Follow-up Neurol 43:2587-2590, Lera,G.,et al, 1993 Multictr Study of Cabergoline, A Long-Acting Dopamine Receptor Agonist, in PD Fluct Resp to Levodopa/Carbidopa Neurol 43:1981-1984, Lieberman,A.,et al, 1993 Showing articles 0 to 9 of 9